- China Oncology Focus has enrolled the first patient in China in the late-stage trial of socazolimab combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer ((ES-SCLC)).
- China Oncology had received exclusive rights to develop and commercialize the antibody for Greater China, which includes Mainland China, Hong Kong, Macau, and Taiwan, from Sorrento (SRNE -4.8%).
- Socazolimab is a fully human anti-PD-L1 monoclonal antibody identified by Sorrento using its proprietary G-MAB library platform.
- The initiation of the trial is based on results from an earlier Phase Ib trial in which socazolimab combined with carboplatin and etoposide showed a promising efficacy and safety profile in patients with ES-SCLC, the company said.
- Socazolimab had won China's NMPA breakthrough therapy status, in February.